How some cancers 'poison the soil' to block metastasis

April 30, 2013

Cancer spread or metastasis can strike unprecedented fear in the minds of cancer patients. The "seed and the soil" hypothesis proposed by Stephen Paget in 1889 is now widely accepted to explain how cancer cells (seeds) are able to generate fertile soil (the microenvironment) in distant organs that promotes cancer's spread. However, this concept does not explain why some tumors do not spread or metastasize.

Scientists at Weill Cornell Medical College have now solved this mystery by showing that metastatic incompetent cancers actually poison the "soil" by generating a that blocks cancer cells from settling and growing in distant organs. Researchers also found that two key proteins involved in this process work by dramatically suppressing cancer's spread.

The study, reported in the April 30 issue of Cancer Discovery, offers hope that a drug based on these potentially therapeutic two proteins, Thrombospondin 1 (Tsp-1)- the poison produced by the microenvironment under the influence of tumor secreted protein prosaposin, might help keep at bay and from metastasizing.

"The majority of cancer-related deaths are due to metastasis, yet there are no approved targeted drugs that have shown significant benefit specifically in treating that spread. We may now finally have a lead on a strategy that could offer us that option for developing and guiding specific anti-metastatic in the clinic," says the study's senior investigator, Dr. Vivek Mittal, an associate professor of cell and in cardiothoracic surgery and director of the Neuberger Berman Foundation Laboratory at Weill Cornell Medical College.

"We have work to do on exploiting these novel insights into fruitful clinical translation, but our findings are, so far, very exciting," says Dr. Mittal.

Researchers from Children's Hospital in Boston, Harvard Medical School and the University of Bergen, Norway, contributed to this study.

Exploit What Nature Has Provided

Scientists have known that all primary tumors do not metastasize, but no one knew what prevented cancer's spread in these "metastasis incompetent" tumors. This new study was conducted to uncover that very mechanism.

"The novel idea was that if we can learn why these certain cancers don't spread, and then we could leverage that knowledge to block metastatic tumors," says Dr. Mittal.

Scientists don't understand why some tumors wouldn't "want" to spread. It goes against their "job description," says Dr. Mittal. He theorizes that metastasis occurs when the barriers that the body throws up to protect itself against cancer fail. But there are some tumors in which some of the barriers may still be intact. "So that suggests those primary tumors will continue to grow, but that an innate protective barrier still exists that prevents them from spreading and invading other organs," says Dr. Mittal.

What the researchers found is that, like typical tumors, metastasis incompetent tumors also send out signaling molecules that establish what is known as the "pre-metastatic niche" in distant organs. These niches comprised of bone marrow cells and various growth factors have been described previously by others including Dr. Mittal as the fertile "soil" that the disseminated cancer cell "seeds" grow in.

Weill Cornell's Dr. Raúl Catena, a postdoctoral fellow in Mittal's laboratory and lead author of the Cancer Discovery study, found an important difference between the tumor types. Metastatic-incompetent tumors systemically increased expression of Tsp-1, a molecule known to fight cancer growth. Importantly, increased Tsp-1 production was found specifically in the bone marrow myeloid cells that comprise the metastatic niche. These results were striking, because for the first time the bone marrow-derived myeloid cells were implicated as the main producers of Tsp-1, says Dr. Mittal.

In addition, Weill Cornell and Harvard researchers found that prosaposin secreted predominantly by the metastatic incompetent tumors, via the blood circulation increased expression of Tsp-1 in the premetastatic lungs. Thus, prosaposin works in combination with Tsp-1 to convert pro-metastatic bone marrow myeloid cells in the niche into cells that are not hospitable to that spread from a primary tumor. "The very same myeloid cells in the niche that we know can promote metastasis can also be induced under the command of the metastatic incompetent primary tumor to inhibit metastasis," Dr. Mittal says.

The research team found that the Tsp-1-inducing activity of prosaposin was contained in only a 5-amino acid peptide region of the protein. This peptide alone induced Tsp-1 in the bone marrow cells and effectively suppressed metastatic spread in the lungs in mouse models of breast and prostate cancer. This 5-amino acid peptide with Tsp-1–inducing activity has the potential to be directly used as a simple and safe therapeutic agent against metastatic cancer. The scientists have begun to test prosaposin in other tumor types or metastatic sites.

"The study's findings have clinical implications," Dr. Mittal says. "Not only is it theoretically possible to design a psosaposin-based drug or drugs that induce Tsp-1 to block cancer spread, but you could potentially create non-invasive prognostic tests to predict whether a cancer will metastasize."

According to researchers, quantifying prosaposin and Tsp-1 in a cancer patient's blood might provide predictions about their tumor's metastatic potential.

"These findings may represent several unique breakthroughs. The study provides a tangible strategy to prevent cancer spread, and this strategy would also be the first to target the microenvironment of the organs the spreads to," Dr. Mittal says.

"Why a would block its ability to invade and spread is puzzling," says Dr. Mittal. "But it is now up to us to exploit clues nature has provided for us to benefit our ."

Explore further: Researchers reveal how cancer cells change once they spread to distant organs

Related Stories

Researchers reveal how cancer cells change once they spread to distant organs

February 22, 2012
Oncologists have known that in order for cancer cells to spread, they must transform themselves so they can detach from a tumor and spread to a distant organ. Now, scientists at Weill Cornell Medical College have revealed ...

Scientists reveal aggressive breast cancer's metastatic path

January 14, 2013
Scientists at Weill Cornell Medical College have discovered the molecular switch that allows aggressive triple negative breast cancer cells to grow the amoeba-like protrusions they need to crawl away from a primary tumor ...

Researchers discover protein that may control the spread of cancer

February 26, 2013
Researchers at the University of Hawai'i Cancer Center have uncovered a novel mechanism that may lead to more selective ways to stop cancer cells from spreading. Associate Professor Joe W. Ramos PhD, a cancer biologist at ...

Cancerous tumors deliver pro-metastatic information in secreted vesicles

May 29, 2012
Cancer researchers have known for well over a century that different tumor types spread only to specific, preferred organs. But no one has been able to determine the mechanisms of organ specific metastasis, the so-called ...

'Fertilizing' bone marrow helps answer why some cancers spread to bones

May 15, 2012
Researchers found that administering a common chemotherapy drug before bone tumors took root actually fertilized the bone marrow, enabling cancer cells, once introduced, to seed and grow more easily.

Recommended for you

Shooting the achilles heel of nervous system cancers

July 20, 2017
Virtually all cancer treatments used today also damage normal cells, causing the toxic side effects associated with cancer treatment. A cooperative research team led by researchers at Dartmouth's Norris Cotton Cancer Center ...

Molecular changes with age in normal breast tissue are linked to cancer-related changes

July 20, 2017
Several known factors are associated with a higher risk of breast cancer including increasing age, being overweight after menopause, alcohol intake, and family history. However, the underlying biologic mechanisms through ...

Immune-cell numbers predict response to combination immunotherapy in melanoma

July 20, 2017
Whether a melanoma patient will better respond to a single immunotherapy drug or two in combination depends on the abundance of certain white blood cells within their tumors, according to a new study conducted by UC San Francisco ...

Discovery could lead to better results for patients undergoing radiation

July 19, 2017
More than half of cancer patients undergo radiotherapy, in which high doses of radiation are aimed at diseased tissue to kill cancer cells. But due to a phenomenon known as radiation-induced bystander effect (RIBE), in which ...

Definitive genomic study reveals alterations driving most medulloblastoma brain tumors

July 19, 2017
The most comprehensive analysis yet of medulloblastoma has identified genomic changes responsible for more than 75 percent of the brain tumors, including two new suspected cancer genes that were found exclusively in the least ...

Novel CRISPR-Cas9 screening enables discovery of new targets to aid cancer immunotherapy

July 19, 2017
A novel screening method developed by a team at Dana-Farber/Boston Children's Cancer and Blood Disorders Center—using CRISPR-Cas9 genome editing technology to test the function of thousands of tumor genes in mice—has ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.